Fierce Biotech May 7, 2024
Max Bayer

Lykos Therapeutics’ MDMA-assisted therapy is charting yet another first in the psychedelic field: an FDA advisory meeting.

The biotech will meet with the Psychopharmacologic Drugs Advisory Committee on June 4, according to a late Monday release. This will be the first time that FDA experts will formally debate a psychedelic treatment. Lykos (formerly known as MAPS PBC) is seeking FDA approval to use MDMA to treat patients with post-traumatic stress disorder. The drug is commonly referred to as ecstasy.

this will also be the first time in 25 years that the FDA will review a new treatment for PTSD, according to Lykos’ announcement.

Lykos has been the leading company in the psychedelic space, a field that has seen...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Mental Health, Pharma / Biotech, Provider
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article